Buscar
Mostrando ítems 11-20 de 24
Desenvolvimento de plataforma biofotônica associada a algoritmos de inteligência artificial para identificação de SARS-CoV-2 em saliva artificialDevelopment of a biophotonic platform associated with artificial intelligence algorithms for the SARS-CoV-2 identification in artificial saliva
(Universidade Federal de UberlândiaBrasilOdontologia, 2022)
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Background A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and
immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine expressing the ...
A Single Dose of a Hybrid hAdV5-Based Anti-COVID-19 Vaccine Induces a Long-Lasting Immune Response and Broad Coverage against VOC
(MDPI, 2021-10)
Most approved vaccines against COVID-19 have to be administered in a prime/boost regimen. We engineered a novel vaccine based on a chimeric human adenovirus 5 (hAdV5) vector. The vaccine (named CoroVaxG.3) is based on three ...
Neutralizing antibodies induced by homologous and heterologous boosters in CoronaVac vaccines in Chile
(2023)
Objectives:To determine the impact of a booster dose on the humoral response in individuals inoculated with a complete schedule of any SARS-CoV-2 vaccine, we evaluated the neutralizing antibody (NAb) titres of homologous ...
Avaliação da resposta neutralizante anti-HIV-1 em indivíduos infectados pelos subtipos virais prevalentes no Brasil em relação às características genéticas e bioquímicas do gene env.
(2016)
Espera-se que uma vacina anti-HIV/aids seja capaz de induzir resposta imune específica de células T CD8+ e de anticorpos neutralizantes (nAb). No entanto, a alta variabilidade genética do envelope (env) viral é um dos ...
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by
vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine ...